Company: STAA
Filing Date: 2025-12-10
Form Type: DEFA14A
Source: 0001193125-25-314435
Chunk: 23

Company: STAAR SURGICAL CO
Filing Date: 2025-12-10
Form: DEFA14A
Chunk 23
---
will be contained in other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available.

16

Annex A

Execution Version

AMENDMENT NO. 2

TO

AGREEMENT AND PLAN OF MERGER

This Amendment No. 2, dated as of December 9, 2025 (this “”), to the Agreement and Plan of Merger, dated
as of August 4, 2025 (the “”), as amended, is by and among Alcon Research, LLC, a Delaware limited liability company (“”), Rascasse Merger Sub, Inc., a Delaware corporation and a
wholly owned direct subsidiary of Parent (“”), and STAAR Surgical Company, a Delaware corporation (the “”). Capitalized terms used and not defined in this Amendment shall have the meanings
ascribed to such terms in the Agreement (as defined below).

WHEREAS, on August 4, 2025, the parties entered into the Initial
Agreement, pursuant to which, among other things, and subject to the terms and conditions therein, Merger Sub will merge with and into the Company, with the Company surviving as a wholly owned direct subsidiary of Parent;

WHEREAS, on November 7, 2025, the parties entered into Amendment No. 1 to the Initial Agreement (the Initial Agreement, as amended,
the “”); and

WHEREAS, pursuant to and in accordance with Section 9.1 of the Agreement, the Parties
desire to amend the Agreement as set forth in this Amendment.

NOW, THEREFORE, in consideration of the mutual agreements set forth in the
Agreement and this Amendment, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

1. . The Agreement is hereby amended as follows:

(a) Recital (A) of the Agreement is hereby amended and restated as follows:

“Parent desires to acquire the Company through a merger of Merger Sub with and into the Company (the “”), with
the Company continuing as the surviving corporation in the Merger (the “”), on the terms and subject to the conditions set forth in this Agreement, whereby (i) each issued and outstanding share of Company
Common Stock (the “”) as of the Effective Time (other than Excluded Shares and Dissenting Shares) will be converted into the right to receive $30.75 per Share, in cash, without interest (the “”), and (ii)